Recorded fact · drug.trial_access

drug.trial_access for palbociclib

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 1b9882c3 resolves to.

The record

Fact id	`1b9882c31ab6e0465e988b06`
Entity	drug: palbociclib
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "PALBOCICLIB",
 "recruitingInterventionalCount": 61,
 "notYetRecruitingCount": 20,
 "byPhase": {
  "PHASE1/PHASE2": 15,
  "PHASE2": 22,
  "PHASE3": 9,
  "PHASE1": 8,
  "EARLY_PHASE1": 1,
  "NA": 6
 },
 "trials": [
  {
   "nctId": "NCT03424005",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2018-03-30",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "France",
    "Germany",
    "Israel",
    "South Korea",
    "Spain",
    "Taiwan",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03424005"
  },
  {
   "nctId": "NCT06126276",
   "briefTitle": "Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2024-05-07",
   "conditions": [
    "Malignant Female Reproductive System Neoplasm",
    "Malignant Solid Neoplasm",
    "Recurrent Malignant Female Reproductive System Neoplasm"
   ],
   "countries": [
    "United States",
    "Puerto Rico"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06126276"
  },
  {
   "nctId": "NCT07174336",
   "briefTitle": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Eli Lilly and Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-12-22",
   "conditions": [
    "Breast Neoplasms",
    "Neoplasm Metastasis"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Belgium",
    "Brazil",
    "Canada",
    "China",
    "France",
    "Germany",
    "Greece"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07174336"
  },
  {
   "nctId": "NCT04802759",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2021-06-22",
   "conditions": [
    "Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Israel",
    "South Korea",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04802759"
  },
  {
   "nctId": "NCT06377852",
   "briefTitle": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "American Society of Clinical Oncology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2024-10-29",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06377852"
  },
  {
   "nctId": "NCT05564377",
   "briefTitle": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2023-04-07",
   "conditions": [
    "Advanced Malignant Solid Neoplasm",
    "Anatomic Stage III Breast Cancer AJCC v8",
    "Anatomic Stage IV Breast Cancer AJCC v8"
   ],
   "countries": [
    "United States",
    "Puerto Rico"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05564377"
  },
  {
   "nctId": "NCT06380751",
   "briefTitle": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-08-01",
   "conditions": [
    "Advanced Breast Cancer"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06380751"
  },
  {
   "nctId": "NCT05696626",
   "briefTitle": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "LeonaBio",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-29",
   "startDate": "2023-10-31",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Belgium",
    "Canada",
    "China",
    "France",
    "Germany",
    "Israel",
    "Italy",
    "Poland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05696626"
  },
  {
   "nctId": "NCT07492641",
   "briefTitle": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "BeOne Medicines",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-26",
   "startDate": "2026-05-22",
   "conditions": [
    "HR+/HER2- Breast Cancer"
   ],
   "countries": [
    "United Stat
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 55b5fc1544e2050f2ec9902dd2d407e48a463a9da1c1b3f9aa5c8882c8d3abfa.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.